Reviews
An update on myositis autoantibodies and insights into pathogenesis
G. Wang1, N.J. Mchugh2
- Department of Rheumatology, Key Myositis Laboratories, China-Japan Friendship Hospital, Beijing, China.
- Department of Life Sciences, University of Bath, UK. prsnjm@bath.ac.uk
CER18124
2025 Vol.43, N°2
PI 0364, PF 0371
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 39480492 [PubMed]
Received: 29/08/2024
Accepted : 28/10/2024
In Press: 31/10/2024
Published: 26/02/2025
Abstract
Myositis-specific autoantibodies (MSAs) are hallmarks of idiopathic inflammatory myopathies (IIMs) and have become increasing valuable in disease diagnosis, phenotyping, and classification. In addition to their clinical utility, emerging data, including findings from several animal studies, suggest that MSAs and autoreactive T cells substantially contribute to the etiopathogenesis of IIMs. This review aims to provide an updated perspective on myositis autoantibodies by focusing on relevant clinical and translational studies.
